scholarly journals NaPi- II b as a potential diagnostic and prognostic biomarker in ovarian cancers

2018 ◽  
Author(s):  
Shoufeng Zhao ◽  
Zhipeng Wang
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cell Line ◽  
Normal Tissues ◽  
Diagnosis And Prognosis ◽  
Kaplan Meier ◽  
Potential Biomarker ◽  
Tumor Types ◽  
First Time ◽  
Kaplan Meier Plotter ◽  
Normal Controls

ABSTRACTOvarian cancer (OC) is commonly diagnosed at an advanced stage due to a lack of effective biomarkers and specificity required for accurate clinical diagnosis. The purpose of this study was to estimate the diagnosis and prognosis of the NaPi- II b in ovarian cancer. Herein, by performing data mining using the databases of Oncomine and Cancer Cell Line Encyclopedia (CCLE), we are for the first time to report that the expression level of NaPi- II b transcripts in a variety of tumor types compared with the normal controls. Based on Kaplan-Meier plotter, we investigated the prognostic values of NaPi- II b specifically high expressed in OC patients. The results of the Oncomine analysis showed that relative expression of NaPi- II b was distinctly high in OC tissues vs. normal tissues. CCLE analysis indicated that the expression of NaPi- II b in OC cell lines expressed the highest level in all cancer lines. In overall survival (OR) analysis, NaPi- II b mRNA high expressions were correlated to worse OR in OC patients. These results indicate that NaPi- II b may be a novel potential biomarker for determining the diagnosis and predicting the prognosis of OC.

scholarly journals Bromine domain protein 4 is an important marker for prognosis of ovarian cancer and tumor immune infiltration

2021 ◽  
Author(s):  
Chujia Chen ◽  
Zhiyong Yang ◽  
Qiuchan Zhao ◽  
Bangming Xu ◽  
Donglin Cao
Keyword(s):  
Ovarian Cancer ◽  
Immune Cell ◽  
Expression Level ◽  
Immune Markers ◽  
Immune Infiltration ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Domain Protein ◽  
Kaplan Meier Plotter

Abstract Background Ovarian cancer (OC) is one of the most common malignant gynecological tumors, but its pathogenesis is unclear. Bromine domain protein 4 (BRD4) is involved in the malignant transformation of cells, as well as the invasion and metastasis of tumor cells. The biological role of BRD4 in ovarian cancer is yet to be determined. Methods The differential expression of BRD4 in OC and corresponding normal tissues was evaluated by exploring the Tumor Immune Assessment Resources (TIMER) and the Oncomine database. The correlation between the expression level of BRD4 and the prognosis of OC patients was evaluated using the Kaplan-Meier Plotter database. Using TIMER, we further studied the correlation between BRD4 and tumor immune cell infiltration. Results The expression of BRD4 was significantly higher in patients with OC, and high BRD4 expression was closely related to low overall survival rate. The BRD4 expression was associated with the levels of immune markers of macrophages, dendritic cells, neutrophils, and various effector T cells. Taken together, these findings show that BRD4 expression is significantly related to immune infiltration in OC and suggest that BRD4 might play an important role in the immune evasion of OC cells. Conclusion The expression level of BRD4 in OC tissues is significantly upregulated, and its high expression is significantly associated with poor prognosis of patients and is closely related to tumor immune infiltration. These results suggest that BRD4 can be used as a prognostic marker and a marker of immune infiltration in OC.

CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma

2020 ◽  
Vol 29 (1) ◽  
pp. 89-99 ◽  
Author(s):  
Jun Wu
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Survival Data ◽  
Transmembrane Domain ◽  
Expression Patterns ◽  
Protein Product ◽  
Normal Tissues ◽  
Diagnosis And Prognosis ◽  
Kaplan Meier ◽  
Kaplan Meier Plotter

BACKGROUND: The CKLF-like MARVEL transmembrane domain-containing family (CMTM) is the protein product of at least one splice variant of each gene contained a Marvel (MAL and related proteins for vesicle trafficking and membrane link) domain, involved in a variety of cellular processes and the pathogenesis of diseases, including tumorigenesis. However, the diverse expression patterns and prognostic values of eight CMTMs have yet to be elucidated. OBJECTIVE: We analyzed the expressions and impacts on survival of different CMTM factors in BC patients to determine their potential diagnosis and prognosis values in BC. METHODS: In the current study, we examined the transcriptional and survival data of CMTMs in patients with breast carcinoma (BC) from ONCOMINE, GEPIA, Kaplan-Meier Plotter, and cBioPortal databases. RESULTS: It was found that CMTM5/7 were down-regulated, whereas CMTM1/6 were up-regulated in BC patients compared with the normal tissues. In survival analyses through the Kaplan-Meier plotter database, increased mRNA expressions of CMTM5/6/7 and decreased mRNA expression of CMTM4 were associated with better relapse-free survival (RFS) of BC patients. CONCLUSIONS: These data provided CMTM5/7 as new biomarker and prognostic factors in BC.

scholarly journals Enabled homolog shown to be a potential biomarker and prognostic indicator for breast cancer by bioinformatics analysis

2019 ◽  
Vol 41 (4) ◽  
pp. E186-E195 ◽  
Author(s):  
Qiang Li ◽  
Yan-Ling Su ◽  
Min Zeng ◽  
Wei-Xi Shen
Keyword(s):  
Breast Cancer ◽  
Cancer Cell ◽  
System Development ◽  
Cancer Cell Line ◽  
Prognostic Indicator ◽  
Nervous System Development ◽  
Luminal B ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Potential Biomarker

Background: Human enabled homolog (ENAH; also known as human ortholog of mammalian enabled, hMENA) is a member of the enabled/vasodilator-stimulated phosphor protein family that regulates fibroblast movement and nervous system development. The ENAH over-expression promotes breast cancer (BC) cell invasion and metastasis. Methods: We studied ENAH mRNA expression in various tumors and normal tissues using the ONCOMINE database, and in an array of cancer cell lines using Cancer Cell Line Encyclopedia data. We also investigated the prognostic value of ENAH expression in patients with BC using Kaplan-Meier plots. Results: Compared with normal tissues, ENAH expression levels were markedly elevated in BC. We identified a correlation between low ENAH and superior relapse-free survival (RFS) of patients with BC; specifically, those with ER(-), HER-2(+), Grade 3 and wild-type TP53 subtypes. Additionally, a correlation was detected between low ENAH and prolonged overall survival of patients with luminal B disease. Conclusion: ENAH is a potential biomarker and important prognostic factor in BC.

scholarly journals Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Min Wu ◽  
Pan Zhang ◽  
Penghui Wang ◽  
Zhen Fang ◽  
Yaqin Zhu
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Prognostic Value ◽  
Diagnostic Value ◽  
Roc Curve Analysis ◽  
Free Survival ◽  
Flap Endonuclease 1 ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Kaplan Meier Plotter

ObjectiveThis study aims to identify the potential value of flap endonuclease 1 (FEN1) as a diagnostic and prognostic marker for breast cancer (BC).MethodsELISA was used to measure serum FEN1 levels and ECLIA for CA153 and CEA levels. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value. Oncomine and UALCAN databases were used to analyze the differences in FEN1 mRNA and protein expressions. Kaplan-Meier Plotter database was then used to assess the prognostic value.ResultsBioinformatics analysis showed that the FEN1 mRNA and protein levels were significantly higher in BC tissues than in normal tissues. FEN1 was detected in culture medium of BC cell lines and serum FEN1 concentrations were significantly increased in BC patients than in cancer-free individuals. Besides, FEN1 exhibited higher diagnostic accuracy (AUC values>0.800) than CA153 and CEA for distinguishing BC patients, especially early BC, from the healthy and benign groups, or individually. Additionally, serum FEN1 levels were significantly associated with the stage (P=0.001) and lymph invasion (P=0.016), and serum FEN1 levels were increased with the development of BC. Furthermore, serum FEN1 levels were significantly decreased in post-operative patients than in pre-operative patients (P=0.016). Based on the Kaplan-Meier Plotter database, the survival analysis indicated that FEN1 overexpression was associated with poor prognoses for overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS) in BC patients.ConclusionFEN1 might be a novel diagnostic and prognostic marker for BC.

scholarly journals DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yang-Jie Wu ◽  
Ai-Tao Nai ◽  
Gui-Cheng He ◽  
Fei Xiao ◽  
Zhi-Min Li ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Roc Curve ◽  
Enrichment Analysis ◽  
Gene Set Enrichment Analysis ◽  
List Type ◽  
Gene Set Enrichment ◽  
Gene Set ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Kaplan Meier Plotter

Abstract Background Dihydropyrimidinase like 2 (DPYSL2) has been linked to tumor metastasis. However, the function of DPSY2L in lung adenocarcinoma (LUAD) is yet to be explored. Methods Herein, we assessed DPYSL2 expression in various tumor types via online databases such as Oncomine and Tumor Immune Estimation Resource (TIMER). Further, we verified the low protein and mRNA expressions of DPYSL2 in LUAD via the ULCAN, The TCGA and GEPIA databases. We applied the ROC curve to examine the role of DPYSL2 in diagnosis. The prognostic significance of DPYSL2 was established through the Kaplan–Meier plotter and the Cox analyses (univariate and multivariate). TIMER was used to explore DPYSL2 expression and its connection to immune infiltrated cells. Through Gene Set Enrichment Analysis, the possible mechanism of DPYSL2 in LUAD was investigated. Results In this study, database analysis revealed lower DPYSL2 expression in LUAD than in normal tissues. The ROC curve suggested that expression of DPYSL2 had high diagnostic efficiency in LUAD. The DPYSL2 expression had an association with the survival time of LUAD patients in the Kaplan–Meier plotter and the Cox analyses. The results from TIMER depicted a markedly positive correlation of DPYSL2 expression with immune cells infiltrated in LUAD, such as macrophages, dendritic cells, CD4+ T cells, and neutrophils. Additionally, many gene markers for the immune system had similar positive correlations in the TIMER analysis. In Gene Set Enrichment Analysis, six immune-related signaling pathways were associated with DPYSL2. Conclusions In summary, DPYSL2 is a novel biomarker with diagnostic and prognostic potential for LUAD as well as an immunotherapy target. Highlights Expression of DPYSL2 was considerably lower in LUAD than in normal tissues. Investigation of multiple databases showed a high diagnostic value of DPYSL2 in LUAD. DPYSL2 can independently predict the LUAD outcomes. Immune-related mechanisms may be potential ways for DPYSL2 to play a role in LUAD.

scholarly journals Transporter Associated with Antigen Processing 1 (TAP1) as a Potential Biomarker for Breast, Lung, Liver and Ovarian Cancer using Health Informatics

2020 ◽  
Author(s):  
Anika Tabassum ◽  
Md. Nazmus Samdani ◽  
Tarak Chandra Dhali ◽  
Rahat Alam ◽  
Foysal Ahammad ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Health Informatics ◽  
Antigen Processing ◽  
Multi Drug Resistance ◽  
P Value ◽  
Mhc I ◽  
Transporter Protein ◽  
Normal Tissues ◽  
Potential Biomarker ◽  
Novel Target

Transporter associated with antigen processing 1 (TAP1) gene codes for a transporter protein, which is responsible for tumor antigen presentation in the MHC I or HLA complex. A defect in the gene results in an inadequate tumor tracking. TAP1 may also influence multi drug resistance, which is an extreme threat in providing treatment by drugs which are chemotherapeutic. The gene of TAP1 was analyzed bioinformatically. It gave us prognostic data as a confirmation of whether it should be used as a biomarker. The expression level and pattern analysis were conducted using ONCOMINE, GENT2 and GEPIA2 online platforms. Samples with different clinical outcomes were investigated for expression and promoter methylation analysis was done in cancer vs normal tissues using UALCAN. The copy number alteration and mutation frequency and expression in different cancer studies were analyzed using cBioPortal. The PrognoScan and KM plotter survival analysis of significant data (p-value<0.05) was representing graphically. Pathway and Gene ontology analysis of gene correlated to TAP1 gene was presented using bar charts. After arranging the data in a single panel and correlating expression to prognosis, understanding mutational and alterations and comparing pathways, TAP1 may be a potential novel target to evade a threat against chemotherapy and the study gives new aspects to consider for immunotherapy in human breast, lung, liver and ovarian cancer.

scholarly journals Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma

2016 ◽  
Vol 40 (3-4) ◽  
pp. 707-715 ◽  
Author(s):  
Ruyi Huang ◽  
Xiaochen Wang ◽  
Wenjie Zhang ◽  
Guangyan Zhangyuan ◽  
Kangpeng Jin ◽  
...  
Keyword(s):  
Roc Curve ◽  
Cox Regression ◽  
Cancer Specific Survival ◽  
Term Survival ◽  
Diagnosis And Prognosis ◽  
Kaplan Meier ◽  
High Expression Group ◽  
Negative Prognostic Factor ◽  
Potential Biomarker ◽  
Low Expression

Background/Aims: Long non-coding RNAs (lncRNAs) have been reported to play pivotal roles in multiple tumors and can act as tumor biomarkers. In this study, we explored the association of the expression of an lncRNA, DGCR5 with clinicopathological features and prognosis in HCC. Methods: Expression levels of DGCR5 were detected by quantitative real-time PCR (qRT-PCR) and the clinical data was obtained, including basic information, data of clinicopathology and cancer specific survival rate. Receiver operating characteristic (ROC) curve, Kaplan-Meier methods and multivariable Cox regression models were used to analyze predictive efficiency, long-term survival outcomes and risk factors. Results: DGCR5 was found down-regulated in HCC tissues (P<0.001) and serum (P = 0.0035) and low expression of DGCR5 was correlated with a poor cancer specific survival (CSS) (P = 0.0019), as the overall 5-year CSS rates were 10.3% (low expression group) and 36.6% (high expression group), respectively. A stratified analysis demonstrated that low DGCR5 expression was an independent negative prognostic factor for HCC. In addition, the area under the ROC curve was 0.782 with a sensitivity of 0.633 and a specificity of 0.833. Conclusions: Our results suggest that DGCR5 may be a participator in HCC and can serve as potential biomarker for the diagnosis and prognosis in HCC.

scholarly journals Predicting STAT1 as a prognostic marker in patients with solid cancer

2020 ◽  
Vol 12 ◽  
pp. 175883592091755
Author(s):  
Jinguo Zhang ◽  
Fanchen Wang ◽  
Fangran Liu ◽  
Guoxiong Xu
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Value ◽  
Renal Carcinoma ◽  
The Cancer Genome Atlas ◽  
Solid Cancer ◽  
Lower Grade ◽  
High Grade ◽  
Large Tumor ◽  
Normal Tissues ◽  
Tumor Types

Background: Aberrant activities of signal transducer and activator of transcription 1 (STAT1) have been implicated in cancer development. However, the prognostic value of STAT1 remains unclear. This report identified the role of STAT1 in prognosis in patients with solid cancer through open literature and The Cancer Genome Atlas (TCGA) database. Methods: Published articles were obtained from PubMed, Web of Science, and Embase databases according to a search strategy up to October 2019. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to assess the prognostic factors of patients. TCGA datasets were used to explore the prognostic value of STAT1 in various cancers. Results: A total of 15 studies incorporating 2839 patients with solid cancers were included. Pooled data showed that overexpressed STAT1 favored long overall survival (OS) (HR = 0.604, 95% CI = 0.431–0.846, p = 0.003) and disease-specific survival (DSS) (HR = 0.650, 95% CI = 0.512–0.825, p = 0.000). In subgroup analyses, highly expressed STAT1 was correlated with long OS of patients with high-grade serous ovarian cancer and oral squamous cell carcinoma. Data extracted from TCGA datasets unveiled that STAT1 expression was significantly higher in 12 cancers (e.g. bladder and breast) than their adjacent normal tissues. Again, highly expressed STAT1 favored long OS of patients with ovarian cancer as well as rectum adenocarcinoma, sarcoma, and skin cutaneous melanoma. However, in renal carcinoma, brain lower grade glioma, lung adenocarcinoma, and pancreatic cancer, highly expressed STAT1 was correlated with poor OS of patients. Particularly in renal carcinoma, increased STAT1 expression was associated with high grade, later stage, large tumor size, and lymph node and distant metastasis. Conclusion: STAT1 has been identified to have prognostic value in patients with solid cancer. Highly expressed STAT1 may predict prognosis in cancer patients based on their tumor types.

scholarly journals Mining expression and prognosis of FOLR1 in ovarian cancer by using Oncomine and Kaplan-Meier plotter

Pteridines ◽  
2019 ◽  
Vol 30 (1) ◽  
pp. 158-164
Author(s):  
Qingyuan Su ◽  
Qingyuan Lv ◽  
Ruijin Wu
Keyword(s):  
Ovarian Cancer ◽  
Mrna Expression ◽  
Ovarian Tumor ◽  
Ovarian Tissue ◽  
Progression Free Survival ◽  
Free Survival ◽  
Normal Ovarian Tissue ◽  
Oncomine Database ◽  
Kaplan Meier ◽  
Kaplan Meier Plotter

Abstract Objective: To further explore folate receptor 1 (FOLR1) gene expression in ovarian cancer and its association with patients’ prognosis by deep mining the Oncomine and Kaplan-Meier plotter databases. Methods: FOLR1 mRNA expression data of ovarian cancer were retrieved from the Oncomine database and further analyzed by comparing tumor to healthy tissue. The prognostic value of FOLR1 in ovarian cancer was analyzed by Kaplan-Meier Plotter, an online survival analysis database. Results A total of 439 studies were included in the Oncomine database in multiple types of cancers. Of the 439 studies, there were 54 with statistical differences for the expression of FOLR1, 19 with increased expression of FOLR1 and 35 with decreased expression comparing ovarian cancer to normal ovary tissue. After searching the Oncomine database, six datasets were discovered comparing the mRNA expression in ovarian tumor to healthy tissue. FOLR1 mRNA expression in ovarian tumor was significantly higher than that of normal ovarian tissue (all p<0.05). The Kaplan-Meier Plotter database analyzed the correlation between FOLR1 expression and ovarian cancer patient’s prognosis. A significant difference of progression-free survival between FOLR1 high and low expressing groups was found in ovarian cancer patients (HR=1.14, 95%CI: 1.00-1.29, p=0.043). However, the overall survival was not statistically different between high and low FOLR1 expressing patients (HR=0.95, 95%CI: 0.84-1.09, p=0.48). Conclusion FOLR1 mRNA was found to be highly expressed in ovarian tumor compared to normal ovarian tissue. Elevated FOLR1 mRNA expression was associated with the poor progression-free survival.

High-Expression HBO1 Predicts Poor Prognosis in Gastric Cancer

2019 ◽  
Vol 152 (4) ◽  
pp. 517-526 ◽  
Author(s):  
Yan Wang ◽  
Sufang Chen ◽  
Wei Tian ◽  
Qing Zhang ◽  
Chunyi Jiang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Messenger Rna ◽  
Origin Recognition Complex ◽  
Tnm Staging ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Serum Carcinoembryonic Antigen ◽  
Polymerase Chain ◽  
Cancer Tissues ◽  
Kaplan Meier Plotter

Abstract Objectives Our goal was to assess the expression of histone acetyltransferase binding to origin recognition complex 1 (HBO1) in gastric cancer and the effect on prognosis for the patients. Methods We used quantitative reverse transcription polymerase chain reaction, Western blot, and tissue microarray immunohistochemistry to investigate the expressions of HBO1 messenger RNA (mRNA) and protein in gastric cancer tissues. Online resources, including Oncomine and Kaplan-Meier Plotter, were used to further assess the correlation between HBO1 expression and the prognosis of the patients with gastric cancer. Results HBO1 mRNA and protein expressions in gastric cancer tissues were both significantly higher than those in normal tissues. The correlations between high HBO1 expression and differentiation, invasive depth (T), lymph node metastasis (N), distant metastasis (M), TNM staging, and serum carcinoembryonic antigen levels were positive. High HBO1 expression was negatively correlated with survival time in patients with gastric cancer. Conclusions HBO1 might be a valuable biomarker to evaluate the prognosis of patients with gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document